Can Emerging Markets Fuel Growth And Restore Trust In Pharma?
This article was originally published in PharmAsia News
Executive Summary
When looking at emerging markets, most biopharma analysts focus on commercial opportunities - whether "pharmerging" markets will help mitigate lost sales in the U.S. and Europe stemming from the patent cliff, increasing pressure from payers and related challenges
You may also be interested in...
Astellas Transfers Compounds To DNDi For Drug Discovery In Chagas, Leishmaniasis and Sleeping Sickness
Astellas and other Japanese pharma have become more open to new partnerships that expand drug access, as well as their market footprint.
Astellas Transfers Compounds To DNDi For Drug Discovery In Chagas, Leishmaniasis and Sleeping Sickness
Astellas and other Japanese pharma have become more open to new partnerships that expand drug access, as well as their market footprint.
Amgen Middle East Regulatory Director On Regulatory Expertise And Drug Pricing - An Interview With PharmAsia News (Part 1 of 2)
Amgen is targeting the Middle East as a new growth area, and it plans to venture further into Gulf countries from Saudi Arabia and war-torn Iraq to countries like Algeria and Libya.